These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

181 related items for PubMed ID: 2437282

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Pharmacological profile of FK480, a novel cholecystokinin type-A receptor antagonist: comparison to loxiglumide.
    Ito H, Sogabe H, Nakarai T, Sato Y, Tomoi M, Kadowaki M, Matsuo M, Tokoro K, Yoshida K.
    J Pharmacol Exp Ther; 1994 Feb; 268(2):571-5. PubMed ID: 7509389
    [Abstract] [Full Text] [Related]

  • 4. Roles of endogenous cholecystokinin in biliary, pancreatic and gastric function: studies with L-364,718, a specific cholecystokinin receptor antagonist.
    Pendleton RG, Bendesky RJ, Schaffer L, Nolan TE, Gould RJ, Clineschmidt BV.
    J Pharmacol Exp Ther; 1987 Apr; 241(1):110-6. PubMed ID: 2437283
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Long-term blockade of cholecystokinin (CCK): effects of L 364,718 (a CCK receptor antagonist) on pancreatic enzyme storage and secretion.
    Rodriguez AI, Manso MA, Garcia-Montero AC, Orfao A, de Dios I.
    Pancreas; 1997 Oct; 15(3):314-22. PubMed ID: 9336798
    [Abstract] [Full Text] [Related]

  • 8. Peripheral biological activity of SR 27897: a new potent non-peptide antagonist of CCKA receptors.
    Gully D, Fréhel D, Marcy C, Spinazzé A, Lespy L, Neliat G, Maffrand JP, Le Fur G.
    Eur J Pharmacol; 1993 Feb 23; 232(1):13-9. PubMed ID: 7681406
    [Abstract] [Full Text] [Related]

  • 9. Anticholecystokinin activities of loxiglumide.
    Setnikar I, Bani M, Cereda R, Chisté R, Makovec F, Pacini MA, Revel L.
    Arzneimittelforschung; 1987 Oct 23; 37(10):1168-71. PubMed ID: 3435589
    [Abstract] [Full Text] [Related]

  • 10. Exocrine effects of the CCK antagonist L-364,718 in canine pancreatic autografts.
    Garvin PJ, Niehoff ML, Burton FR, Dysarz FA, Meadow R, Solomon H.
    J Surg Res; 1996 Feb 15; 61(1):256-9. PubMed ID: 8769975
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. SR146131: a new potent, orally active, and selective nonpeptide cholecystokinin subtype 1 receptor agonist. II. In vivo pharmacological characterization.
    Bignon E, Alonso R, Arnone M, Boigegrain R, Brodin R, Gueudet C, Héaulme M, Keane P, Landi M, Molimard JC, Olliero D, Poncelet M, Seban E, Simiand J, Soubrié P, Pascal M, Maffrand JP, Le Fur G.
    J Pharmacol Exp Ther; 1999 May 15; 289(2):752-61. PubMed ID: 10215649
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Cholecystokinin antagonistic activities of loxiglumide.
    Wakatsuki K, Saito T, Saeki M, Ninomiya K, Kasai H, Kimura K, Fujii M.
    Arzneimittelforschung; 1997 Oct 15; 47(10):1130-3. PubMed ID: 9368707
    [Abstract] [Full Text] [Related]

  • 15. Effect of CCK antagonist L 364718 on meal-induced pancreatic secretion in rats.
    O'Rourke MF, Reidelberger RD, Solomon TE.
    Am J Physiol; 1990 Feb 15; 258(2 Pt 1):G179-84. PubMed ID: 1689547
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Pharmacological profile of T-0632, a novel potent and selective CCKA receptor antagonist, in vivo.
    Taniguchi H, Yazaki N, Yomota E, Shikano T, Endo T, Nagasaki M.
    Eur J Pharmacol; 1996 Sep 26; 312(2):227-33. PubMed ID: 8894600
    [Abstract] [Full Text] [Related]

  • 18. Evidence for two cholecystokinin receptors mediating the contraction of the guinea pig isolated ileum longitudinal muscle myenteric plexus.
    Dal Forno G, Pietra C, Urciuoli M, van Amsterdam FT, Toson G, Gaviraghi G, Trist D.
    J Pharmacol Exp Ther; 1992 Jun 26; 261(3):1056-63. PubMed ID: 1602372
    [Abstract] [Full Text] [Related]

  • 19. Pharmacological properties of lorglumide as a member of a new class of cholecystokinin antagonists.
    Makovec F, Bani M, Cereda R, Chisté R, Pacini MA, Revel L, Rovati LA, Rovati LC, Setnikar I.
    Arzneimittelforschung; 1987 Nov 26; 37(11):1265-8. PubMed ID: 3440035
    [Abstract] [Full Text] [Related]

  • 20. Effect of the novel cholecystokinin receptor antagonist CR-1392 on cholecystokinin-induced antroduodenal and pyloric motor activity in vivo.
    Allescher HD, Daniel EE, Fox JE, Kostolanska F, Rovati LA.
    J Pharmacol Exp Ther; 1989 Dec 26; 251(3):1134-41. PubMed ID: 2600808
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.